oxidopamine has been researched along with Glial Cell Tumors in 7 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giuliani, P | 1 |
| Ballerini, P | 1 |
| Buccella, S | 1 |
| Ciccarelli, R | 1 |
| Rathbone, MP | 1 |
| Romano, S | 1 |
| D'Alimonte, I | 1 |
| Caciagli, F | 1 |
| Di Iorio, P | 1 |
| Pokorski, M | 1 |
| Massie, A | 1 |
| Schallier, A | 1 |
| Kim, SW | 1 |
| Fernando, R | 1 |
| Kobayashi, S | 1 |
| Beck, H | 1 |
| De Bundel, D | 1 |
| Vermoesen, K | 1 |
| Bannai, S | 1 |
| Smolders, I | 1 |
| Conrad, M | 1 |
| Plesnila, N | 1 |
| Sato, H | 1 |
| Michotte, Y | 1 |
| Zhang, Y | 1 |
| Schlachetzki, F | 1 |
| Zhang, YF | 1 |
| Boado, RJ | 1 |
| Pardridge, WM | 1 |
| Mazzio, EA | 1 |
| Kolta, MG | 1 |
| Reams, RR | 1 |
| Soliman, KF | 1 |
| Zuo, D | 1 |
| Yu, PH | 1 |
| Trejo, F | 1 |
| Vergara, P | 1 |
| Brenner, M | 1 |
| Segovia, J | 1 |
| Bing, G | 1 |
| Notter, MF | 1 |
| Hansen, JT | 1 |
| Kellogg, C | 1 |
| Kordower, JH | 1 |
| Gash, DM | 1 |
7 other studies available for oxidopamine and Glial Cell Tumors
| Article | Year |
|---|---|
Guanosine protects glial cells against 6-hydroxydopamine toxicity.
Topics: Animals; Apoptosis; Astrocytes; Biological Transport; Butadienes; Cell Line, Tumor; Chromones; DNA F | 2015 |
Dopaminergic neurons of system x(c)⁻-deficient mice are highly protected against 6-hydroxydopamine-induced toxicity.
Topics: Aging; Amino Acid Transport System y+; Animals; Corpus Striatum; Cystine; Dopamine; Glioma; Glutamic | 2011 |
Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter.
Topics: Animals; Antibodies, Monoclonal; Blood-Brain Barrier; Cell Nucleus; Central Nervous System Neoplasms | 2004 |
Inhibitory effects of cigarette smoke on glial inducible nitric oxide synthase and lack of protective properties against oxidative neurotoxins in vitro.
Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Survival; Glioma; Hydrogen Peroxide; Monoamine Ox | 2005 |
Increase of survival of dopaminergic neuroblastoma in co-cultures with C-6 glioma by R-(-)-deprenyl.
Topics: Brain Neoplasms; Cell Survival; Dopamine; Dose-Response Relationship, Drug; Glioma; Humans; Neurobla | 1995 |
Gene therapy in a rodent model of Parkinson's disease using differentiated C6 cells expressing a GFAP-tyrosine hydroxylase transgene.
Topics: Animals; Cell Transplantation; Genetic Therapy; Glial Fibrillary Acidic Protein; Glioma; Humans; Mal | 1999 |
Cografts of adrenal medulla with C6 glioma cells in rats with 6-hydroxydopamine-induced lesions.
Topics: Adrenal Medulla; Catecholamines; Corpus Striatum; Glioma; Graft Survival; Hydroxydopamines; Immunohi | 1990 |